Filozofija antifilozofije u islamu

In this article, I will examine Aristotle’s protreptic argument for the necessity of philosophy as it was deployed by Al-Kindi. I will show how a Muslim critic of philosophy, primarily one who is aligned with the theological outlook of Ibn Hanbal, can reasonably reject the protreptic argument as Al-Kindi presents it. The argument can, however, be reworked in a way to circumvent common criticisms of it presented by Hanbalī-style opponents of philosophy. Indeed, I will argue that, once the argument is properly clarified with reference to what constitutes ‘philosophy’, its soundness is incontrovertible. In closing, I will briefly discuss why Muslim critics of philosophy need not see the protreptic argument as threatening, as the inevitability of philosophy does not necessitate a commitment to all sorts of philosophical positions, however problematic these may be for Islamic doctrine.U ovom ću članku razmotriti Aristotelov protreptički argument za nužnost filozofije kako ga je postavio Al-Kindi. Pokazat ću kako muslimanski kritičar filozofije, prvenstveno onaj koji je usklađen s teološkim stajalištima Ibn Hanbala, može s razlogom odbaciti protreptički argument kako ga predstavlja Al-Kindi. Međutim, argument se može preraditi na način da se zaobiđu uobičajene kritike koje iznose protivnici filozofije u stilu Hanbalīja. Dapače, tvrdit ću da je njegova ispravnost neupitna jednom kad se argument pravilno razjasni s obzirom na to kako se treba shvatiti \u27filozofiju\u27. Na kraju ću ukratko raspravljati o tome zašto muslimanski kritičari filozofije ne moraju smatrati protreptički argument problematičnim, budući da neizbježnost filozofije ne zahtijeva privrženost svim vrstama filozofskih pozicija, koliko god one bile problematične za islamsku doktrinu

Traditional Islamic Exclusivism –A Critique

In this paper, I give an account and critique of what I call ”Traditional Islamic Exclusivism’ -- a specific Islamic interpretation of religious exclusivism. This Islamic version of religious exclusivism rests on exclusivist attitudes towards truth, epistemic justification and salvation. After giving an account of Traditional Islamic Exclusivism by explaining its theological roots in the Qur’an and ahadith, I proceed to critique it. I do so by arguing that Islamic epistemic exclusivism, which forms the main core of Traditional Islamic Exclusivism, is implausible. This criticism subsequently opens up further lines of criticism and discussion of both salvific and alethic exclusivism in an Islamic context. I conclude with some remarks about the implications and significance of my criticisms of Traditional Islamic Exclusivism

STRUCTURAL PROPERTIES OF NITROGEN DOPED ANATASE AND RUTILE TiO2 THIN FILMS

Anatase and rutile TiO2 thin films have been doped by N ion implantation. The effect of N doping on the structural changes of TiO2 thin films and its correlation to the optical and chemical properties of the films is investigated. The depth and concentration of the implanted N atoms is found not to exhibit substantial difference for anatase and rutile phases. The energy loss of the implanted N atoms correlates well to the energy gained by O and Ti atoms in the TiO2 lattice. An increased number of O vacancies are found to be generated as compared to Ti for both anatase and rutile phases. The energy loss mechanisms of the implanted N atoms together with the O vacancy generation are found to be the major driving forces for facilitating enhanced optical and chemical properties of the TiO2 thin films

A Checklist of Ants (Hymenoptera: Formicidae) in Pakistan

The present paper provides an updated checklist of the ants (Hymenoptera: Formicidae) of Pakistan. These include seven of the 21 known extant subfamilies with 101 valid ant species in 33 genera. Five species are reported for the first time from Pakistan: Cardiocondyla wroughtonii Forel, 1890; Crematogaster biroi Mayr, 1897; Ooceraea biroi (Forel, 1907); Pseudoneoponera rufipes Jerdon, 1851 and Strumigenys godeffroyi Mayr, 1866. Images to scientifically validate new faunal records from Pakistan and facilitate prompt identification are provided. Among the newly recorded species, three species viz., C. wroughtonii; O. biroi and S. godeffroyi are considered as tramp species having the cosmopolitan distribution. Notes about type localities, depositories and distribution in Pakistan are provided to each species record. The list provides a synthesis of the regional taxonomical work carried out until now and will serve as a baseline survey for future studies

A Novel Way Of Repair Of Insulation Breaks During Pacemaker Generator Replacement

Minor abrasions can occur while mobilising old lead during pacemaker generator replacement necesittating placement of additional lead adding to the financial burden and junk in heart. We describe a novel way of repair of old pacemaker lead preventing additional lead placement

Meroterpenoids: A Comprehensive Update Insight on Structural Diversity and Biology.

Funder: This research was funded by the Deanship of Scientific Research at Princess Nourah bint Abdulrahman University through the Fast-track Research Funding ProgramMeroterpenoids are secondary metabolites formed due to mixed biosynthetic pathways which are produced in part from a terpenoid co-substrate. These mixed biosynthetically hybrid compounds are widely produced by bacteria, algae, plants, and animals. Notably amazing chemical diversity is generated among meroterpenoids via a combination of terpenoid scaffolds with polyketides, alkaloids, phenols, and amino acids. This review deals with the isolation, chemical diversity, and biological effects of 452 new meroterpenoids reported from natural sources from January 2016 to December 2020. Most of the meroterpenoids possess antimicrobial, cytotoxic, antioxidant, anti-inflammatory, antiviral, enzyme inhibitory, and immunosupressive effects

Effects of a high-dose 24-h infusion of tranexamic acid on death and thromboembolic events in patients with acute gastrointestinal bleeding (HALT-IT): an international randomised, double-blind, placebo-controlled trial

Background: Tranexamic acid reduces surgical bleeding and reduces death due to bleeding in patients with trauma. Meta-analyses of small trials show that tranexamic acid might decrease deaths from gastrointestinal bleeding. We aimed to assess the effects of tranexamic acid in patients with gastrointestinal bleeding. Methods: We did an international, multicentre, randomised, placebo-controlled trial in 164 hospitals in 15 countries. Patients were enrolled if the responsible clinician was uncertain whether to use tranexamic acid, were aged above the minimum age considered an adult in their country (either aged 16 years and older or aged 18 years and older), and had significant (defined as at risk of bleeding to death) upper or lower gastrointestinal bleeding. Patients were randomly assigned by selection of a numbered treatment pack from a box containing eight packs that were identical apart from the pack number. Patients received either a loading dose of 1 g tranexamic acid, which was added to 100 mL infusion bag of 0·9% sodium chloride and infused by slow intravenous injection over 10 min, followed by a maintenance dose of 3 g tranexamic acid added to 1 L of any isotonic intravenous solution and infused at 125 mg/h for 24 h, or placebo (sodium chloride 0·9%). Patients, caregivers, and those assessing outcomes were masked to allocation. The primary outcome was death due to bleeding within 5 days of randomisation; analysis excluded patients who received neither dose of the allocated treatment and those for whom outcome data on death were unavailable. This trial was registered with Current Controlled Trials, ISRCTN11225767, and ClinicalTrials.gov, NCT01658124. Findings: Between July 4, 2013, and June 21, 2019, we randomly allocated 12 009 patients to receive tranexamic acid (5994, 49·9%) or matching placebo (6015, 50·1%), of whom 11 952 (99·5%) received the first dose of the allocated treatment. Death due to bleeding within 5 days of randomisation occurred in 222 (4%) of 5956 patients in the tranexamic acid group and in 226 (4%) of 5981 patients in the placebo group (risk ratio [RR] 0·99, 95% CI 0·82–1·18). Arterial thromboembolic events (myocardial infarction or stroke) were similar in the tranexamic acid group and placebo group (42 [0·7%] of 5952 vs 46 [0·8%] of 5977; 0·92; 0·60 to 1·39). Venous thromboembolic events (deep vein thrombosis or pulmonary embolism) were higher in tranexamic acid group than in the placebo group (48 [0·8%] of 5952 vs 26 [0·4%] of 5977; RR 1·85; 95% CI 1·15 to 2·98). Interpretation: We found that tranexamic acid did not reduce death from gastrointestinal bleeding. On the basis of our results, tranexamic acid should not be used for the treatment of gastrointestinal bleeding outside the context of a randomised trial

Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial

Background: Short-term treatment for people with type 2 diabetes using a low dose of the selective endothelin A receptor antagonist atrasentan reduces albuminuria without causing significant sodium retention. We report the long-term effects of treatment with atrasentan on major renal outcomes. Methods: We did this double-blind, randomised, placebo-controlled trial at 689 sites in 41 countries. We enrolled adults aged 18–85 years with type 2 diabetes, estimated glomerular filtration rate (eGFR)25–75 mL/min per 1·73 m 2 of body surface area, and a urine albumin-to-creatinine ratio (UACR)of 300–5000 mg/g who had received maximum labelled or tolerated renin–angiotensin system inhibition for at least 4 weeks. Participants were given atrasentan 0·75 mg orally daily during an enrichment period before random group assignment. Those with a UACR decrease of at least 30% with no substantial fluid retention during the enrichment period (responders)were included in the double-blind treatment period. Responders were randomly assigned to receive either atrasentan 0·75 mg orally daily or placebo. All patients and investigators were masked to treatment assignment. The primary endpoint was a composite of doubling of serum creatinine (sustained for ≥30 days)or end-stage kidney disease (eGFR <15 mL/min per 1·73 m 2 sustained for ≥90 days, chronic dialysis for ≥90 days, kidney transplantation, or death from kidney failure)in the intention-to-treat population of all responders. Safety was assessed in all patients who received at least one dose of their assigned study treatment. The study is registered with ClinicalTrials.gov, number NCT01858532. Findings: Between May 17, 2013, and July 13, 2017, 11 087 patients were screened; 5117 entered the enrichment period, and 4711 completed the enrichment period. Of these, 2648 patients were responders and were randomly assigned to the atrasentan group (n=1325)or placebo group (n=1323). Median follow-up was 2·2 years (IQR 1·4–2·9). 79 (6·0%)of 1325 patients in the atrasentan group and 105 (7·9%)of 1323 in the placebo group had a primary composite renal endpoint event (hazard ratio [HR]0·65 [95% CI 0·49–0·88]; p=0·0047). Fluid retention and anaemia adverse events, which have been previously attributed to endothelin receptor antagonists, were more frequent in the atrasentan group than in the placebo group. Hospital admission for heart failure occurred in 47 (3·5%)of 1325 patients in the atrasentan group and 34 (2·6%)of 1323 patients in the placebo group (HR 1·33 [95% CI 0·85–2·07]; p=0·208). 58 (4·4%)patients in the atrasentan group and 52 (3·9%)in the placebo group died (HR 1·09 [95% CI 0·75–1·59]; p=0·65). Interpretation: Atrasentan reduced the risk of renal events in patients with diabetes and chronic kidney disease who were selected to optimise efficacy and safety. These data support a potential role for selective endothelin receptor antagonists in protecting renal function in patients with type 2 diabetes at high risk of developing end-stage kidney disease. Funding: AbbVie